Developments in Neuroprotection for HIV-Associated Neurocognitive Disorders (HAND).
Dennis L KolsonPublished in: Current HIV/AIDS reports (2022)
Successes in modifying cART regimens for CNS efficacy (penetrance, chemokine receptor targeting) and delivery (nanoformulations) in pilot studies suggest that improving cART neuroprotection and reducing HAND risk is achievable. Additionally, drugs currently used in neuroinflammatory, neuropsychiatric, and metabolic disorders show promise as adjuncts to cART, likely by broadly targeting neuroinflammation, oxidative stress, aerobic metabolism, and/or neurotransmitter metabolism. Adjunctive cognitive brain therapy and aerobic exercise may provide additional efficacy. Adjunctive neuroprotective therapies, including available FDA-approved drugs, cognitive therapy, and aerobic exercise combined with improved cART offer plausible strategies for optimizing the prevention and treatment of HAND.
Keyphrases
- cerebral ischemia
- oxidative stress
- blood brain barrier
- subarachnoid hemorrhage
- brain injury
- cancer therapy
- antiretroviral therapy
- human immunodeficiency virus
- hiv positive
- hiv infected
- traumatic brain injury
- hepatitis c virus
- bipolar disorder
- hiv testing
- randomized controlled trial
- high intensity
- white matter
- drug delivery
- stem cells
- ischemia reperfusion injury
- lipopolysaccharide induced
- study protocol
- bone marrow
- lps induced
- binding protein
- multiple sclerosis
- men who have sex with men
- inflammatory response
- case control
- replacement therapy